Results 21 to 30 of about 8,720 (195)

Cilostazol for Secondary Prevention of Stroke and Cognitive Decline: Systematic Review and Meta-Analysis [PDF]

, 2020
Background and Purpose: Cilostazol, a phosphodiesterase 3’ inhibitor, is used in Asia-Pacific countries for stroke prevention, but rarely used elsewhere.
McHutchison, Caroline, Gordon W. Blair, Caroline McHutchison, Appleton, Jason P., Bath, Philip M, Blair, Gordon W., Blair, Gordon W, Francesca M. Chappell, Bath, Philip M., Jason P. Appleton, Philip M. Bath, Fergus Doubal, Wardlaw, Joanna M, Appleton, Jason P, Chappell, Francesca M, Doubal, Fergus, Chappell, Francesca M., Wardlaw, Joanna M., Joanna M. Wardlaw   +18 more
core   +1 more source

Cilostazol Attenuates AngII-Induced Cardiac Fibrosis in apoE Deficient Mice [PDF]

, 2022
Cardiac fibrosis is characterized by the net accumulation of extracellular matrix in the myocardium and is an integral component of most pathological cardiac conditions.
Umebayashi, Ryoko, Uchida, Haruhito A., Wada, Jun, Hada, Yoshiko, Yoshida, Masashi   +4 more
core   +2 more sources

Repurposing cilostazol for raynaud's phenomenon [PDF]

, 2021
Raynaud's Phenomenon (RP) results from exaggerated cold-induced vasoconstriction. RP patients suffer from vasospastic attacks and compromised digital blood perfusion leading to a triple color change at the level the fingers.
Baydoun, Elias Abdel Hasan, El Hachem, Nehme, Fardoun, Manal Muin, Eid, Ali H., Slika, Hasan, Fardoun, Manal M., Baydoun, Elias, El-Hachem, Nehme   +7 more
core   +1 more source

Cilostazol use is associated with FIM cognitive improvement during convalescent rehabilitation in patients with ischemic stroke: a retrospective study [PDF]

, 2019
2019-08Cilostazol is a phosphodiesterase III-inhibiting antiplatelet agent that is often used to prevent stroke and peripheral artery disease, and its administration has shown significant improvements for cognitive impairment.
Nakagawa-Senda, Hiroko, Ishiguro, Naoki, Senda, Joe, Kishimoto, Hideo, Kanamori, Masahiko, Wakai, Kenji, Katsuno, Masahisa, Kotake, Tomomitsu, Nishida, Yoshihiro, Ito, Keiichi, Kadono, Izumi   +10 more
core   +1 more source

Effect of cilostazol on arteriovenous fistula in hemodialysis patients

Nefrología (English Edition), 2021
Background: The maturation and patency of permanent vascular access are critical in patients requiring hemodialysis. Although numerus trials have been attempted to achieve permanently patent vascular access, little have been noticeable.
Jae Wan Jeon, Hae Ri Kim, Eujin Lee, Jong In Lee, Young Rok Ham, Ki Ryang Na, Kang Wook Lee, Jwa-Jin Kim, Dae Eun Choi   +8 more
doaj   +3 more sources

Cilostazol Upregulates Autophagy via SIRT1 Activation: Reducing Amyloid-β Peptide and APP-CTFβ Levels in Neuronal Cells. [PDF]

PLoS ONE, 2015
Autophagy is a vital pathway for the removal of β-amyloid peptide (Aβ) and the aggregated proteins that cause Alzheimer's disease (AD). We previously found that cilostazol induced SIRT1 expression and its activity in neuronal cells, and thus, we ...
Hye Rin Lee, Hwa Kyoung Shin, So Youn Park, Hye Young Kim, Sun Sik Bae, Won Suk Lee, Byung Yong Rhim, Ki Whan Hong, Chi Dae Kim   +8 more
doaj   +1 more source

Cilostazol Induces PGI2 Production via Activation of the Downstream Epac-1/Rap1 Signaling Cascade to Increase Intracellular Calcium by PLCε and to Activate p44/42 MAPK in Human Aortic Endothelial Cells.

PLoS ONE, 2015
BackgroundCilostazol, a selective phosphodiesterase 3 (PDE3) inhibitor, is known as an anti-platelet drug and acts directly on platelets. Cilostazol has been shown to exhibit vascular protection in ischemic diseases. Although vascular endothelium-derived
Ayako Hashimoto, Michinori Tanaka, Satoshi Takeda, Hideki Ito, Keisuke Nagano   +4 more
doaj   +1 more source

Cilostazol-induced acute tubulointerstitial nephritis accompanied by IgA nephropathy: a case report

BMC Nephrology, 2018
Background Cilostazol is an antiplatelet drug that is widely prescribed for the prevention of secondary stroke. Adverse reactions to cilostazol include headaches, palpitations, and diarrhea. Little is known about the nephrotoxicity of cilostazol, such as
Hisato Shima, Manabu Tashiro, Satoshi Yamada, Motokazu Matsuura, Kazuyoshi Okada, Toshio Doi, Jun Minakuchi, Shu Kawashima   +7 more
doaj   +1 more source

The protective effect of cilostazol on isolated rabbit femoral arteries under conditions of ischemia and reperfusion: the role of the nitric oxide pathway

Clinics, 2012
OBJECTIVES: The clinical significance of ischemia/reperfusion of the lower extremities demands further investigation to enable the development of more effective therapeutic alternatives.
Mariana R.G.A. Santos, Andréa C. Celotto, Verena K. Capellini, Paulo R. B. Evora, Carlos E. Piccinato, Edwaldo E. Joviliano   +5 more
doaj   +1 more source

5. THE EFFECT OF CILOSTAZOL TO ARTERIAL STIFFNESS IN THE HYPERTENSIVE PATIENT

Artery Research, 2009
Background: Cilostazol is a potent antiplatelet agent that selectively inhibits phosphodiesterase III, and also it has beneficial effect to peripheral arterial disease, like intermittent claudication, by direct vasodilative action.
Jin Oh Na, Chang-Gyu Park, Cheol-Ung Choi, Soon-Yong Suh, Eung-Ju Kim, Seung-Woon Rha, Jin-Won Kim, Hong-Seog Seo, Dong-Joo Oh   +8 more
doaj   +1 more source